•Japan's Financial Services Agency (FSA) reclassified XRP from a speculative cryptoasset to a regulated financial instrument under the Financial Instruments and Exchange Act.
•The move is expected to broaden institutional access and deepen XRP's role within Japan's mainstream payments infrastructure.
•The Phase 3 SCOUT-HCM trial demonstrated the efficacy and safety of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
•Data was presented at the American College of Cardiology (ACC) conference, reinforcing the drug's safety and efficacy profile in a younger demographic.
